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Cancer is the number two killer in the
United States and will probably account for
some 400,000 deaths in 1982 . The lung has
now achieved the dubious distinction of being
the most common site of cancer in men and
causes the most deaths. Cancer of the colon
and rectum is the second most common cancer
in both males and females combined, whereas
carcinoma of the breast and uterus predominate in women.
The incidence of most cancers has been
rising rather slowly over the past several decades for reasons that are not clear, possibly because of increasing contamination of our environment by chemical carcinogens, air pollution,
and prescription drugs. In males lung cancer
has dwarfed the incidence of most of the other
tumors ; even in females there is an ominous recent sharp angling of the curve upward . Carcinoma of the stomach and carcinoma of the cervix have markedly declined during the past
several years, but the reason for this is unclear.
Perhaps the decline may be related to some
dietary factor which has been eliminated due to
better techniques for preserving or preparing
meat.
It is useful to examine the anticipated fiveyear cancer survival rates for specific sites
taken from the Surveillance Epidemiology End
Results Group of the National Cancer Institute.
Many localized cancers, particulary those of the
bladder, breast , colon , larynx, prostate and
uterus, show prolonged survival times. The notable exception is the lung with a five-year survival of only 23%, even if the tumor is localized
at the time of surgery. The American Cancer
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Society purports to indicate that this means tumors should be detected earlier. An alternative
explanation is that those tumors which remain
localized are biologically less malignant and
grow more slowly, and therefore have a greater
likelihood of being found at a time when they
have not yet spread.
· What is not emphasized is that for prostatic neoplasms and lung cancer , probably 8085% of the tumors are disseminated when first
discovered, so that the localized cancers are in
the distinct minority. Once a tumor has been
disseminated, the chances for prolonging survival are greatly diminished .
During the past five years there have been
no substantially new modalities of therapy . In
some areas our surgical techniques are already
extremely refined while in other areas they continue to evolve , as in the currently expanding
use of microsurgery in pituitary, pineal , ocular,
and laryngeal tumors . There has been a proliferation of endoscopists, and it is now a rare endobronchial, colonic, or jejunal lesion that manages to escape direct visual inspection through
the endoscope befpre it is removed .
Substantial advances have been made in
diagnostic radiology, particularly in the areas of
CT scanning and ultrasound . Radiotherapeutic
techniques have gradually evolved as well.
Treatment planning is better because of newer
computer-simulated models. The high-voltage
linear accelerator and the use of newer heavy
particles, such as the neutron and photon
beams , have also given a higher therapeutic index in specific problems.
The cumulative impact of these refine-

ments in surgery, radiology, and chemotherapy
has been substantial. For example, in radiotherapy there has been great improvement in
survival for those who have tumors that are both
radiosensitive and tend to be localized . There is
little question that we have markedly improved
the therapeutic index in retinoblastoma, testicular carcinoma, Hodgkin disease, and have improved the situation in head and neck cancer,
as well as prostate, bladder, ovary, and tonsil
cancer.
More striking is that a number of cancers,
particulary congenital trophoblastic tumors, Burkitt lymphoma, testicular neoplasms, Wilms
tumor, and neuroblastoma are now being cured
routinely by chemotherapy. Hodgkin disease
has been heavily affected by appropriately used
radiation therapy and chemotherapy, sometimes in combination. Survival of patients with
Hodgkin disease in 1979 is probably greater
than 50% for all tumors. Chemotherapy is also
generally agreed to be useful for palliation of
prostatic carcinoma and breast carcinoma as
well as chronic lymphocytic leukemia, lymphosarcoma, and acute myeloblastic leukemia.
We have not changed survival times of patients with the more common solid tumors to
any extent despite the progress we have made
in controlling the fluid tumors of leukemia and
lymphoma. Little progress has been made in
prolonging survival of patients with solid organ
tumors, particularly those of the lung, colon,
and genitourinary tract which are the most common and which far outnumber leukemias and
lymphomas. Nevertheless, a great deal of progress has been made during the past decade.
We have learned much about the biological behavior of human tumors, some from animal experimentation and some from carefully
designed cooperative clinical trials. There are
two important concepts which have had considerable impact: first, the concept of micrometastases and their relationship to tumor burden,
particularly in breast cancer; and second, differences in biologic aggressiveness among histologically-similar types of cancer as exemplified
by Hodgkin disease.
With respect to the concept of total tumor
burden and micrometastases, it should first be
stressed that all tumors, when discovered, are
actually in a fairly late stage of their growth . If
we assume that a tumor begins as a single cell
and continues doubling and growing ex-

ponentially, it has already divided approximately
30 times to reach a size of about 1 0 8 or 1 09
cells and a weight of about one gram. A one-cm
tumor nodule is probably at the limit of detection
either by palpation or x-ray.
Treatment may accomplish any of several
goals. An effective treatment may shrink the tumor drastically, perhaps by a factor of a thousand, but unless every cell is destroyed , it is almost certain that the tumor will recur. If the
recurrent tumor tends to follow the same kinetics as the earlier tumor, its rate of growth will be
the same. This is usually the case except in the
case of metastatic tumors; such tumors usually
grow faster. In general, the more substantial the
response, the longer the survival.
In some instances effective treatment,
such as hormonal therapy, may drive the tumor
into a state of dormancy or quiescence, so that
its rate of growth is changed, but at some later
point when it resumes autonomous growth, it
will again grow at a rate similar to the rate it exhibited initially or even faster.
Many chemotherapists have spoken of
eradication of the last tumor cell. We now know
that this is somewhat naive and may perhaps
apply to one or two tumors in which most all the
cells are actively growing and are susceptible to
a chemotherapeutic agent. In the most common
solid tumors such as those of the lung, breast,
and colon , only a portion of the cells are in
cycle and are susceptible to chemotherapy at
any one time.
It is likely that many tumors continually
shed cells into the circulation, and the cells that
are shed must be counted in the total tumor burden. There was an experiment which was performed in mice in which an implanted mammary
carcinoma was allowed to grow to the size of
700 mg. At that time surgery was performed,
and all visible tumor was excised. Nevertheless,
it was clear that there must have been micrometastases at sites distant from the resection because with large tumors essentially no mice remained tumor free one month after surgery.
There is a striking parallelism between this
experiment and a similar study performed in humans where the tumor burden was simply measured by the number of positive lymph nodes
found during surgery in patients with breast carcinoma. As the number of positive nodes increased , the ten-year survival of these patients
fell drastically. A number of surgeons claim that
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patients with higher numbers of positive lymph
nodes do poorly because the nodes act as a
secondary focus of disease and that more extensive operations should be performed.
If this thesis were correct, then there
should be clearly demonstrable differences between patients that had different types of operations. The newer operation that is now being
performed is a simple or total mastectomy in
which just the breast is removed, but the contents of the axilla are not taken (they may be
biopsied but are not removed), and the pectoralis muscle is also preserved. This is to be
compared with a standard radical mastectomy
in which the entire contents of the axilla are removed together with the pectoralis muscle,
leaving only the intercostal muscles and the ribs
after mastectomy.
After five years the National Surgical Adjuvant Breast Protocol Groups have shown no difference in survival among almost 1 ,000 patients who underwent different types of
mastectomy. This would affirm that the reason
for failure of breast carcinoma treatment is due
to distant metastases which are not visible at
the time of surgery. This concept has had an
enormous impact on the area of breast cancer
because it has led to trials of adjuvant chemotherapy which have, in fact, greatly improved
survival where surgery could not.
In Hogkin disease we have a similar situation but with one additional complicating factor.
First, we do know that in Hodgkin disease the
total body burden of the disease does bear a
close relationship to prognosis. Early in the
treatment of Hodgkin disease, many of the observers at Stanford and other institutions concluded that most Hodgkin disease spread by
contiguity and that the disease essentially could
be cured if radiotherapy could be applied to all
the involved fields plus an additional margin of
safety around the field. Thus, Stage I could be
treated by radiotherapy to the axilla and the mediastinum.
An additional important prognostic factor
in Hodgkin disease is the histologic type of the
disease. Four current histologic classifications
are recognized : lymphocytic predominance,
nodular sclerosis, mixed cellularity, and lymphoid depletion. In this progression the last type
has the most Reed-Sternberg cells, the least
lymphocytes, and the worst prognosis, no matter what the stage. Each of these histologic pre-
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sentations is closely associated with a specific
stage of the disease; for example, lymphoid depletion is extremely rare in Stage I and is most
found in Stage Ill or IV. On the other hand, lymphocytic predominance is usually found as
Stage I or Stage II. Although there is some overlap between histologic patterns of the disease,
in the main the histologic patterns tend to persist for long periods of time.
It is beginning to appear that Hodgkin disease may consist of at least four separate clinical entities, each of which pursues a different
course and for which different management
strategies are indicated. For Hodgkin sarcoma,
which tends to disseminate rapidly and probably does not spread by contiguity, localized radiotherapy would be useless and systemic chemotherapy would be the more effective agent.
Similarly, for lymphocytic predominance, chemotherapy would probably represent too much
treatment. An important corollary has been that
the presence of systemic symptoms indicates
that the disease is aggressive and probably will
also require systemic treatment . Thus, even if
the disease is Stage II during intensive investigation but systemic symptoms are present, the
recurrence rate after radiotherapy only is high
so that chemotherapy should be considered
even at that early stage.
There are other examples of tumors of different biologic aggressiveness. It is easy to recall the difference in aggressiveness, growth
rate and prognosis in patients with estrogen-receptor positive and estrogen-receptor negative
breast cancer. In malignant melanoma as well,
it has become apparent that certain types of
melanoma, particularly the lentigo maligna or
the superficial spreading melanoma, are much
less virulent than the nodular melanoma. This
undoubtedly will be important at a later time in
treatment, but as yet no effective treatment regimen has been designed for any of these stages.
Another important topic for which great interest has been generated during the past decade is that of the possibility of immunotherapy,
that is to say, that of immunizing the patient
against his own tumor. Unfortunately, this treatment will also have to await the future because
there is no firm evidence that immunizing patients with their own tumor in any way has altered survival or produced regression of the disease on its own. When used in combination with
chemotherapy, most controlled studies have not

indicated that there is any additional benefit of
adding immunotherapy, although the work is
not yet completed. One of the important dividends of immunotherapeutic research has been
the notion that there are certain antigens on the
surfaces of tumor cells which may be important
in diagnosis and detection.
The carcinoembryonic antigen (CEA) is a
specific antigen which is represented on the
surface of colonic tumors and also on the surface of the fetal colon as well. The tum9r sheds
CEA into the serum, and this can be detected
by radioimmunoassay . Whereas CEA levels
have not been found to be particularly useful in
the detection and screening of coionic carcinoma, they have been valuable for following the
course of the patient after surgery. Typically,
normal patients do not have CEA levels above
five nanograms per ml; colon cancer patients
. may have much higher levels~ If resection is

successful and complete, the levels fall rapidly
after operation . In 30-40% of cases, the CEA
rises several months before recurrence is Clinically detectable.
In acute myeloblastic leukemia we have
been carrying out similar experiments at this institution in conjunction With the University of Toronto, and we have been performing tests on
bone marrow of leukemia patients in remission
to determine whether we mjght predict relapse
at an earlier time. Some of our data on 43 patients will soon be published in the New England
Journal of Medicine.
This suggests that tests can be devised
which will pick up impending relapse in patients
with myeloblastic leukemia approximately four
to five months before the tumor appears in the
bone marrow. We hope to exploit this fact by
applying reinduction chemotherapy at an earlier
stage.
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